Hepatitis C virus

Phase I

This study is ongoing, but not recruiting participants.

The purpose of this study is to evaluate the safety, tolerability and immunogenicity of VGX-6150 as a second-line therapy in chronic hepatitis C patients.

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (VGX-6150-01).

VGX-6150-01

INO-8000/VGX-6150

For more information please go to the study protocol.



Hepatitis B virus

Phase I

This study is currently recruiting participants.

This study is an open-label study to evaluate the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding HBsAg and HBcAg) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation (EP) in 126 (one hundred twenty six) entecavir or tenofovir treated HBeAg positive patients.

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, HBeAg+, Chronic Hepatitis B Patients.

HBV-001

INO-1800

For more information please go to the study protocol.

 


Ebola

Phase I

This study is ongoing, but not recruiting participants.

This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be tolerated and immunogenic.

Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers.

EBOV-001

INO-4212

For more information please go to the study protocol.

 


HIV, providing coverage against global HIV clades

Phase I

This study is currently recruiting participants.

The purpose of this study is to evaluate the safety and tolerability of the PENNVAX®-GP HIV-1 DNA vaccine with or without interleukin 12 (IL-12) DNA adjuvant, given by intradermal or intramuscular injection with electroporation, in healthy, HIV-uninfected adults. The trial will measure immune responses following administration of the vaccine, which targets two env antigens as well as gag and pol antigens—providing global coverage against HIV-1 subtypes— in four groups of healthy subjects.

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults.

HVTN 098, 11890

PENNVAX®-GP

For more information please go to the study protocol.

 


HIV, clades A, C, and D

Phase I

This study has been completed.

The purpose of this study is to evaluate the safety of and immune response to a primate vaccination with a synthetic DNA vaccine for the HIV subtypes A,C and D followed by a boost with a viral vector based HIV vaccine.

A Study of the Safety and Immunogenicity of PENNVAX®-G DNA (Env & Gag) Administered by Intramuscular Biojector 2000 or CELLECTRA® Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) Boost in Healthy, HIV Uninfected Adults

RV 262

PENNVAX®-G

For more information please go to the study protocol.


Middle East respiratory syndrome (MERS)

Phase I

This study is currently recruiting participants.

The Middle East Respiratory Syndrome Coronavirus (MERS CoV), a virus related to Severe Acute respiratory syndrome coronavirus (SARS CoV), was first recognized as a cause of severe pulmonary infection in 2012. Infection with MERS CoV has been diagnosed in more than 1600 individuals with a mortality rate between 35% and 40%. GLS-5300 is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein. This study will evaluate the safety of GLS-5300 at one of three dose levels following a three-injection vaccination regimen followed by electroporation. The study will also assess immune responses over a 1 year period with respect to the generation of antibody and cellular responses.

Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers

NCT02670187

GLS-5300

For more information please go to the study protocol.


Zika virus

Phase I

This study is currently recruiting participants.

The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700, a synthetic DNA vaccine against the Zika virus. ZIKA-001 is the first in man clinical trial of this vaccine, which encodes for the pre-membrane, membrane and envelope regions of Zika virus.

Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults

NCT02809443

GLS-5700

For more information please go to the study protocol.